Creating new tests for dangerous infections and antibiotic resistance
Official title: Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections, and Emerging Infectious Diseases
Funded at Clear Labs, INC. · NIH-11196799 · Data updated 2026-11-12
This study is working on new ways to quickly and accurately find germs that can cause serious illnesses, helping doctors diagnose infections faster and improve treatment for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clear Labs, INC. NIH-funded |
| Lab location | 1 site (Menlo Park, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $2,443,961 |
| NIH project number | 75N93024C00052-0-9999-1 |
| Project ID | NIH-11196799 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for infections caused by antibiotic-resistant bacteria or emerging infectious diseases.
✕Less likely to help
Patients with infections that are not caused by the targeted pathogens or those who do not require advanced diagnostic testing may not benefit from this research.
What this research studies
This research focuses on developing advanced diagnostic technologies to detect pathogens that pose biothreats and those responsible for emerging infectious diseases. It aims to enhance the performance of nucleic acid sequencing methods and improve the detection of proteins in blood and other biofluids. By refining these diagnostic tools, the research seeks to enable quicker and more accurate identification of infections, which can lead to better patient management and treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnoses of serious infections, improving treatment options for patients.
How similar studies have gone: Previous research has shown success in developing diagnostic technologies for infectious diseases, indicating a promising potential for this approach.
Where this research is happening
-
Clear Labs, INC.
Menlo Park, United States Active
Researchers
- Principal investigator: Khaksar, Ramin — Clear Labs, INC.
- Study coordinator: Khaksar, Ramin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.